A combination of aerobic exercise and resistance exercise is most effective for reducing liver fat, according to a review of data from appropriately controlled clinical…
News
ALAGILLE SYNDROME
NewsAlagille Syndrome Awareness Day seeks to unite global community
International Alagille Syndrome Awareness Day is tomorrow, Jan. 24, and the advocacy organization Alagille Syndrome Alliance is calling on the community to stand together…
After about two years of treatment with the experimental therapies tobevibart and elebsiran, nearly nine out of 10 evaluable…
CHOLANGITIS
NewsGenetic analysis unveils 3 potentially key treatment targets for PSC
Researchers have identified three proteins that may be key targets for treating primary sclerosing cholangitis (PSC), and one of these proteins may also be…
CHOLESTASIS
NewsEarly trial results testing maralixibat for hard-to-treat itching due by year’s end
A global clinical trial testing Mirum Pharmaceuticals‘ maralixibat for treatment-resistant itching, or pruritus, associated with rare cholestatic conditions is expected to complete patient…
BILIARY ATRESIA
NewsBiliary atresia treatment AX-0810 faring well in early testing
AX-0810, an experimental treatment for biliary atresia and primary sclerosing cholangitis (PSC), has so far been well tolerated in early clinical testing. Initial…
HEPATITIS
NewsClinical trial results support bepirovirsen for hepatitis B
Bepirovirsen added to standard-of-care medications led to higher functional cure rates for people with chronic hepatitis B than standard treatments alone, according to top-line…
Vitamin D was shown to ease the effects of liver inflammation and damage in primary biliary cholangitis (PBC), a chronic form of cholangitis,…
Low vitamin D levels in the first trimester of pregnancy are significantly associated with an increased risk of developing intrahepatic cholestasis of pregnancy (ICP),…
FATTY LIVER DISEASE
NewsMadrigal acquires ervogastat to help boost MASH treatment options
Madrigal Pharmaceuticals, the maker of Rezdiffra (resmetiron), has acquired three new experimental treatments for metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty…
Recent Posts
- Putting out the fires of inflammation in liver disease
- Change is good, but in life with MASH, it’s important to start small
- It turns out that having great friends is good for my health
- With Alagille syndrome, summer fun comes with a summer caution
- Gene therapy shows early promise for fatal childhood liver disease